Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ate1 shRNA is a short hairpin RNA designed to silence the expression of Arginyltransferase 1 (Ate1). Ate1 is an enzyme responsible for arginylation, a post-translational modification that has been implicated in cellular stress responses and genomic stability. Research in prostate cancer models, specifically using LnCaP and PC-3 cell lines, has identified Ate1 as a potential suppressor of metastasis. Silencing Ate1 with shRNA has been shown to increase anchorage-independent growth and matrigel invasion in vitro. Furthermore, in vivo studies involving orthotopic implantation of Ate1-silenced PC-3 cells in immunocompromised mice demonstrated significantly higher levels of metastasis compared to control cells, suggesting that the loss of Ate1 promotes cancer progression and metastatic phenotypes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ate1 shRNA.